本帖最后由 老马 于 2012-1-13 21:20 编辑
, M! f+ x* c6 Y8 A, N0 W# a4 B& k
/ C8 q2 g/ h: \爱必妥和阿瓦斯丁的比较
' K7 h& o/ B6 n4 w! C
6 w0 F+ |9 z7 Qhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 R2 C8 @, g4 B
+ g: F: y l* S; X# L: E% \" B
9 a& @- r0 u7 I- ?% G4 |% `http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ U2 H9 C6 q; W( h==================================================
8 i r2 x, `1 i& m$ h( qOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% }. e( `5 j! ~. XPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 J% H+ W1 L* b/ H, C6 `2 qResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' ^+ f& \+ f9 C
|